COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009)XXX final

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include acrolein as an active substance in Annex I thereto

Draft

COMMISSION DIRECTIVE ../…/EC

of

amending Directive 98/8/EC of the European Parliament and of the Council to include acrolein as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular Article 11(4) thereof,

Whereas:

(1) The United Kingdom has received on 18 August 2006 an application from Baker Petrolite, in accordance with Article 11(1) of Directive 98/8/EC, for the inclusion of the active substance acrolein in its Annex I for use in product-type 12, slimicides, as defined in Annex V to Directive 98/8/EC. Acrolein was not on the market on the date referred to in Article 34(1) of Directive 98/8/EC as an active substance of a biocidal product.

(2) After carrying out an evaluation, the United Kingdom submitted its report, together with a recommendation, to the Commission on 16 March 2009.

(3) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2], the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 18 September 2009, in an assessment report.

(4) It appears from the examinations made that biocidal products used as slimicides and containing acrolein may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC. It is therefore appropriate to include acrolein in Annex I.

---

1 OJ L 123, 24.4.1998, p. 1.
2 OJ L 325, 11.12.2007, p. 3.

(5) Not all potential uses have been evaluated at the Community level. It is therefore appropriate that Member States assess those uses or exposure scenarios and those risks to compartments and populations that have not been representatively addressed in the Community level risk assessment and, when granting product authorisations, ensure that appropriate measures are taken or specific conditions imposed in order to reduce the identified risks to acceptable levels.

(6) In the light of the findings of the assessment report, it is appropriate to require that risk mitigation measures are applied at product authorisation level to products containing acrolein used as slimicides.

(7) In particular, it is appropriate to require that products intended for industrial or professional use be used with appropriate protective equipment and that safe operational procedures are established such as the use of air monitoring and exclusion zones, unless it can be demonstrated that risks for industrial or professional users can be reduced by other means.

(8) Appropriate measures should be taken to limit the risks to the marine environment, since unacceptable risks to this compartment have been identified during the evaluation. To this end, certain conditions should be imposed by the competent authorities when authorising the biocidal product, namely ensuring that waste water is monitored and, if necessary, treated before discharge.

(9) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States to bring into force the laws, regulations and administrative provisions necessary to comply with this Directive.

(10) Directive 98/8/EC should therefore be amended accordingly.

(11) The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 98/8/EC is amended in accordance with the Annex to this Directive.

Article 2

1. Member States shall adopt and publish the laws, regulations and administrative provisions necessary to comply with this Directive by 31 August 2010 at the latest.

   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

The following entry for the substance acrolein is added in Annex I to Directive 98/8/EC:

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry da
"(**) [OPOCE: please insert substance number]	Acrolein	Acrylaldehyde EC No: 203-453-4 CAS No: 107-02-8	963 g/kg	1 September 2010	Not applicable	31 Augus

(*) For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009) XXX final

Draft

COMMISSION DECISION

of […]

concerning the non-inclusion of diazinon in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market

Draft

COMMISSION DECISION

of

concerning the non-inclusion of diazinon in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC.

(2) Diazinon is included in that list for use in product-type 18, insecticides, acaricides and products to control other arthropods, as defined in Annex V to Directive 98/8/EC.

(3) The deadline for the submission of a complete dossier for active substances for use in product-type 18 was 30 April 2006. No complete dossier was however received within this time period.

(4) The Commission informed the Member States accordingly. On 14 June 2006, the Commission also made that information public by electronic means.

(5) Within the period of three months from that publication, a company indicated an interest in taking over the role of participant for diazinon for use in product-type 18.

(6) Commission Decision 2007/794/EC of 29 November 2007[3] fixed the new deadline for the submission of a dossier to 30 April 2008.

---

1 OJ L 123, 24.4.1998, p. 1.
2 OJ L 325, 11.12.2007, p. 3.
3 OJ L 320, 6.12.2007, p. 35.

(7) Within this new deadline, before submitting its dossier, the applicant consulted Portugal, the Rapporteur Member State designated for the evaluation of diazinon, to enquire whether its reference product, a flea collar, was to be considered as a biocidal product or a veterinary medicinal product.

(8) Portugal, after consultation with the Commission and the other Member States, advised the applicant that most Member States would not consider a flea collar such as the one placed on the market by the applicant as a biocidal but as a veterinary medicinal product, as defined in Article 1(2) of Directive 2001/82/EC.

(9) In view of this advice the applicant did not submit a dossier for the inclusion of diazinon in Annex I, IA or IB to Directive 98/8/EC for product-type 18. Pursuant to Article 12(4) of Regulation (EC) No 1451/2007, the role of participant for diazinon for product-type 18 may no longer be taken over.

(10) Since the applicant did not submit a dossier within the prescribed period, diazinon should not be included for product-type 18 in Annexes I, IA or IB to Directive 98/8/EC.

(11) It is necessary to establish a longer period for the phasing-out of flea collars placed on the market of certain Member States as biocidal products to allow for their authorisation as veterinary medicinal products in accordance with Directive 2001/82/EC.

(12) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Biocidal Products.

HAS ADOPTED THIS DECISION:

Article 1

Diazinon (CAS number 333-41-5, EC number 206-373-8) shall not be included in Annexes I, IA or IB to Directive 98/8/EC for product type 18.

Article 2

Flea collars placed on the market as biocidal products and containing diazinon for use in product type 18 shall no longer be placed on the market with effect from 1 March 2013.

Other biocidal products containing diazinon for use in product type 18 shall no longer be placed on the market with effect from 1 March 2011.

Article 3

This Decision is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros Dimas
Member of the Commission

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009)XXX final

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include brodifacoum as an active substance in Annex I thereto

EN

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include brodifacoum as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market [2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes brodifacoum.

(2) Pursuant to Regulation (EC) No 1451/2007, brodifacoum has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.

(3) Italy was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 5 June 2005 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.

---

1 OJ L 123, 24.4.1998, p. 1.
2 OJ L 325, 11.12.2007, p. 3.

(4) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 20 February 2009, in an assessment report.

(5) It appears from the examinations made that biocidal products used as rodenticides and containing brodifacoum may be expected not to present a risk to humans except for accidental incidents with children. A risk has been identified regarding non-target animals and the environment. However, the target rodents are vermin and thus constitute a danger to public health. Moreover, it has not yet been established that adequate alternatives to brodifacoum exist, which are both equally effective and less damaging to the environment. It is therefore justified to include brodifacoum in Annex I for a limited period, in order to ensure that in all Member States authorisations for biocidal products used as rodenticides and containing brodifacoum can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.

(6) In the light of the findings of the assessment report, it is appropriate to require that specific risk mitigation measures are applied at product authorisation level to products containing brodifacoum and used as rodenticides. Such measures should be aimed at limiting the risk of primary and secondary exposure of humans and non-target animals as well as the long term effects of the substance on the environment. To this end, certain constraints such as the maximum concentration, the prohibition on marketing the active substance in products used as tracking powder or in products which are not ready for use, and the use of aversive agents should be imposed across the board, while other conditions should be imposed by the Member States on a case by case basis.

(7) Because of the identified risks and its characteristics, which render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, brodifacoum should be included in Annex I for five years only and should be made subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in Annex I is renewed.

(8) It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance brodifacoum and also to facilitate the proper operation of the biocidal products market in general.

(9) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States and the interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.

(10) After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 14 containing brodifacoum to ensure that they comply with Directive 98/8/EC.

(11) Directive 98/8/EC should therefore be amended accordingly.

(12) The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 98/8/EC is amended in accordance with the Annex to this Directive.

Article 2

1. Member States shall adopt and publish, by 30 June 2010 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.

   They shall apply those provisions from 1 July 2011.

   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

The following entry 'No. 25' is inserted in Annex I to Directive 98/8/EC:

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions*
"25	brodifacoum	3-[3-(4'-bromobiphenyl-4-yl)-1,2,3,4-tetrahydro-1-napthyl]-4-hydroxycoumarin EC No: 259-980-5 CAS No: 56073-10-0	950 g/kg	1 July 2011	30 June 2013	30 June 2016	14	In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance in the products shall not exceed 50 mg/kg and only ready-for-use products shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Products shall not be used as tracking powder. (4) Primary as well as secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes."

(*) For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009) XXX final

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include aluminium phosphide releasing phosphine as an active substance in Annex I thereto

Draft

COMMISSION DIRECTIVE ../…/EC

of

amending Directive 98/8/EC of the European Parliament and of the Council to include aluminium phosphide releasing phosphine as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes aluminium phosphide.

(2) Commission Directive 2009/XXX/EC[3] included aluminium phosphide as an active substance in Annex I to Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.

(3) Pursuant to Regulation (EC) No 1451/2007, aluminium phosphide has now been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 18, insecticides, as defined in Annex V to that Directive.

(4) Germany was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 26 October 2007 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.

(5) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the

---

1 OJ L 123, 24.4.1998, p. 1.
2 OJ L 325, 11.12.2007, p. 3.
3 OJ L XXX, XX.XX.2009, p. XX

findings of the review were incorporated, within the Standing Committee on Biocidal Products on 15 May 2009, in an assessment report.

(6) It appears from the examinations made that biocidal products used as insecticides and containing aluminium phosphide may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC. It is therefore appropriate to include aluminium phosphide in Annex I, in order to ensure that in all Member States authorisations for biocidal products used as insecticides and containing aluminium phosphide can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.

(7) Not all potential uses have been evaluated at the Community level. It is therefore appropriate that Member States assess those uses or exposure scenarios and those risks to the compartments and populations that have not been representatively addressed in the Community level risk assessment and, when granting product authorisations, ensure that appropriate measures are taken or specific conditions imposed in order to reduce the identified risks to acceptable levels. In particular, where relevant, Member States should assess outdoor use, which has not been addressed in the Community level risk assessment.

(8) In the light of the conclusions of the assessment report, it is appropriate to require that products containing aluminium phosphide and used as insecticides be authorised only for use by trained professionals in accordance with Article 10(2)(i)(e) of Directive 98/8/EC, and that specific risk mitigation measures are applied at product authorisation level to such products. Such measures should be aimed at limiting the risk of exposure of users to aluminium phosphide to an acceptable level.

(9) Regulation (EC) 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC[4] establishes maximum limits for aluminium phosphide residues which are present in or on food and feed as a result of use as a biocide. Member States should ensure that adequate residue trials are provided at product authorisation to allow consumer risk assessment and should also take measures such as the adherence to waiting periods to ensure that maximum residue limits laid down in Regulation (EC) 396/2005 are not exceeded.

(10) It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance aluminium phosphide and also to facilitate the proper operation of the biocidal products market in general.

(11) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States and the interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.

---

[4] OJ L 70, 16.3.2005, p. 1.

(12) After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 18 containing aluminium phosphide to ensure that they comply with Directive 98/8/EC.

(13) Directive 98/8/EC should therefore be amended accordingly.

(14) The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 98/8/EC is amended in accordance with the Annex to this Directive.

Article 2

1. Member States shall adopt and publish, by 30 September 2010 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.

   They shall apply those provisions from 1 October 2011.

   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

The following is added to entry ‘No. 20’ in Annex I to Directive 98/8/EC:

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions (*)

			"830 g/kg	1 October 2011	30 September 2013	30 September 2021	18	When assessing the application for authorisation of a product in accordan with Article 5 and Annex VI, Member States shall assess, when relevant f the particular product, those uses or exposure scenarios and those risks compartments and populations that have not been representatively address in the Community level risk assessment. In particular, where releva Member States shall assess outdoor use. When granting product authorisation, Member States shall ensure th adequate residue trials are provided to allow consumer risk assessment a that appropriate measures are taken or specific conditions imposed in order mitigate the identified risks. Member States shall ensure that authorisations are subject to the followi conditions: (1) Products shall only be supplied to and used by specifically train professionals in the form of ready-for-use products. (2) In view of the risks identified for operators, appropriate ri mitigation measures must be applied. Those include, amon others, the use of appropriate personal and respiratory protecti equipment, the use of applicators and the presentation of t product in a form designed to reduce the exposure of operators an acceptable level. For indoor use, those include also t protection of operators and workers during fumigation, t protection of workers at re-entry (after fumigation period) and t protection of bystanders against leaking of gas. (3) For products containing aluminium phosphide that may lead residues in food or feed, labels and/or safety data sheets mu contain instructions for use, such as the adherence to waiti periods, which ensure that MRLs set out in Regulation (E No 396/2005 of the European Parliament and of the Council(*)a not exceeded. (*) OJ L 70, 16.3.2005, p. 1."

(*) For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009) XXX final

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include magnesium phosphide releasing phosphine as an active substance in Annex I thereto

Draft

COMMISSION DIRECTIVE ../…/EC

of

amending Directive 98/8/EC of the European Parliament and of the Council to include magnesium phosphide releasing phosphine as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes magnesium phosphide.

(2) Pursuant to Regulation (EC) No 1451/2007, magnesium phosphide has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 18, insecticides, as defined in Annex V to that Directive.

(3) Germany was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 26 October 2007 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.

(4) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 15 May 2009, in an assessment report.

(5) It appears from the examinations made that biocidal products used as insecticides and containing magnesium phosphide may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC. It is therefore appropriate to include

[1] OJ L 123, 24.4.1998, p. 1.
[2] OJ L 325, 11.12.2007, p. 3.

magnesium phosphide in Annex I, in order to ensure that in all Member States authorisations for biocidal products used as insecticides and containing magnesium phosphide can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.

(6) Not all potential uses have been evaluated at the Community level. It is therefore appropriate that Member States assess those uses or exposure scenarios and those risks to the compartments and populations that have not been representatively addressed in the Community level risk assessment and, when granting product authorisations, ensure that appropriate measures are taken or specific conditions imposed in order to reduce the identified risks to acceptable levels. In particular, where relevant, Member States should assess outdoor use, which has not been addressed in the Community level risk assessment.

(7) In the light of the conclusions of the assessment report, it is appropriate to require that products containing magnesium phosphide and used as insecticides be authorised only for use by trained professionals in accordance with Article 10(2)(i)(e) of Directive 98/8/EC, and that specific risk mitigation measures are applied at product authorisation level to such products. Such measures should be aimed at limiting the risk of exposure of users to magnesium phosphide to an acceptable level.

(8) Regulation (EC) 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC[3] establishes maximum limits for magnesium phosphide residues which are present in or on food and feed. Pursuant to Article 3(2)(c) of Regulation (EC) 396/2005, the maximum residue limits apply to any pesticide residues, including those which may arise as a result of use as a biocide. Member States should ensure that adequate residue trials are provided at product authorisation to allow consumer risk assessment and should also take measures such as the adherence to waiting periods to ensure that maximum residue limits laid down in Regulation (EC) 396/2005 are not exceeded.

(9) It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance magnesium phosphide and also to facilitate the proper operation of the biocidal products market in general.

(10) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States and the interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.

(11) After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 18 containing magnesium phosphide to ensure that they comply with Directive 98/8/EC.

---

[3] OJ L 70, 16.3.2005, p. 1.

(12) Directive 98/8/EC should therefore be amended accordingly.

(13) The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 98/8/EC is amended in accordance with the Annex to this Directive.

Article 2

1. Member States shall adopt and publish, by 30 September 2010 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.

   They shall apply those provisions from 1 October 2011.

   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

The following entry ‘No. 30’ is inserted in Annex I to Directive 98/8/EC:

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions (*)

"30	Magnesium phosphide releasing phosphine	Trimagnesium diphosphide EC No: 235-023-7 CAS No: 12057-74-8	880 g/kg	1 October 2011	30 September 2013	30 September 2021	18	When assessing the application for authorisation of a product in accorda with Article 5 and Annex VI, Member States shall assess, when relevant the particular product, those uses or exposure scenarios and those risk compartments and populations that have not been representatively addresse the Community level risk assessment. In particular, where relevant, Mem States shall assess outdoor use. When granting product authorisation, Member States shall ensure adequate residue trials are provided to allow consumer risk assessment that appropriate measures are taken or specific conditions imposed in orde mitigate the identified risks. Member States shall ensure that authorisations are subject to the follow conditions: (1) Products shall only be supplied to and used by specifically tra professionals in the form of ready-for-use products. (2) In view of the risks identified for operators, appropriate mitigation measures must be applied. Those include, amo others, the use of appropriate personal and respiratory protec equipment, the use of applicators and the presentation of product in a form designed to reduce the exposure of operator an acceptable level. For indoor use, those include also protection of operators and workers during fumigation, protection of workers at re-entry (after fumigation period) and protection of bystanders against leaking of gas. (3) For products containing magnesium phosphide that may lea residues in food or feed, labels and/or safety data sheets m contain instructions for use, such as the adherence to wai periods, which ensure that MRLs set out in Regulation (No 396/2005 (*) are not exceeded. (*) OJ L 70, 16.3.2005, p. 1."

(*) For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009) XXX final

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin sodium as an active substance in Annex I thereto

Draft

COMMISSION DIRECTIVE ../…/EC

of

amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin sodium as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes warfarin sodium.

(2) Pursuant to Regulation (EC) No 1451/2007, warfarin sodium has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.

(3) Ireland was designated as Rapporteur Member State and submitted its report, together with a recommendation, to the Commission on 3 October 2005 in accordance with Article 14(4) and 14(6) of Regulation (EC) No 1451/2007.

(4) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 18 September 2009, in an assessment report.

(5) It appears from the examinations made that biocidal products used as rodenticides and containing warfarin sodium may be expected not to present a risk to humans except for accidental incidents with children. A risk has been identified regarding non-target

[1] OJ L 123, 24.4.1998, p. 1.
[2] OJ L 325, 11.12.2007, p. 3.

animals. However, warfarin sodium is for the time being considered essential for reasons of public health and hygiene. It is therefore appropriate to include warfarin sodium in Annex I, in order to ensure that in all Member States authorisations for biocidal products used as rodenticides and containing warfarin sodium can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.

(6) In the light of the findings of the assessment report, it is appropriate to require that specific risk mitigation measures are applied at product authorisation level to products containing warfarin sodium and used as rodenticides. Such measures should be aimed at limiting the risk of primary and secondary exposure of humans and non-target animals. To this end, certain constraints such as the maximum concentration, the prohibition on marketing the active substance in products which are not ready to use and the use of aversive agents should be imposed for all rodenticides containing warfarin sodium, while other conditions should be imposed by the Member States on a case by case basis.

(7) In view of the identified risks, warfarin sodium should be included in Annex I for five years only and should be made subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in Annex I is renewed.

(8) It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance warfarin sodium and to facilitate the proper operation of the biocidal products market in general.

(9) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States to bring into force the laws, regulations and administrative provisions necessary to comply with this Directive.

(10) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States and the interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.

(11) After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 14 containing warfarin sodium to ensure that they comply with Directive 98/8/EC.

(12) Directive 98/8/EC should therefore be amended accordingly.

(13) The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 98/8/EC is amended in accordance with the Annex to this Directive.

Article 2

1. Member States shall adopt and publish, by 31 January 2011 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.

   They shall apply those provisions from 1 February 2012.

   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

The following entry for the substance warfarin sodium is added in Annex I to Directive 98/8/EC:

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions (*)
"(**) [OPOCE: please insert substance number]	Warfarin sodium	Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate EC No: 204-929-4 CAS No: 129-06-6	910 g/kg	1 February 2012	31 January 2014	31 January 2017	14	The active substance shall be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance shall not exceed 790 mg/kg and only ready-for-use baits shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Primary and secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the possibility of restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions (*)
								boxes."

(*) For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009)XXX final

Draft

COMMISSION DIRECTIVE ../…/EC

of […]

amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin as an active substance in Annex I thereto

Draft

COMMISSION DIRECTIVE ../…/EC

of

amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes warfarin.

(2) Pursuant to Regulation (EC) No 1451/2007, warfarin has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.

(3) Ireland was designated as Rapporteur Member State and submitted its report, together with a recommendation, to the Commission on 3 October 2005 in accordance with Article 14(4) and 14(6) of Regulation (EC) No 1451/2007.

(4) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 18 September 2009, in an assessment report.

(5) It appears from the examinations made that biocidal products used as rodenticides and containing warfarin may be expected not to present a risk to humans except for accidental incidents with children. A risk has been identified regarding non-target

[1] OJ L 123, 24.4.1998, p. 1.
[2] OJ L 325, 11.12.2007, p. 3.

animals. However, warfarin is for the time being considered essential for reasons of public health and hygiene. It is therefore appropriate to include warfarin in Annex I, in order to ensure that in all Member States authorisations for biocidal products used as rodenticides and containing warfarin can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.

(6) In the light of the findings of the assessment report, it is appropriate to require that specific risk mitigation measures are applied at product authorisation level to products containing warfarin and used as rodenticides. Such measures should be aimed at limiting the risk of primary and secondary exposure of humans and non-target animals. To this end, certain constraints such as the maximum concentration, the prohibition on marketing the active substance in products which are not ready to use and the use of aversive agents should be imposed for all rodenticides containing warfarin, while other conditions should be imposed by the Member States on a case by case basis.

(7) In view of the identified risks, warfarin should be included in Annex I for five years only and should be made subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in Annex I is renewed.

(8) It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance warfarin and to facilitate the proper operation of the biocidal products market in general.

(9) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States to bring into force the laws, regulations and administrative provisions necessary to comply with this Directive.

(10) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States and the interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.

(11) After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 14 containing warfarin to ensure that they comply with Directive 98/8/EC.

(12) Directive 98/8/EC should therefore be amended accordingly.

(13) The measures provided for in this Directive are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Annex I to Directive 98/8/EC is amended in accordance with the Annex to this Directive.

Article 2

1. Member States shall adopt and publish, by 31 January 2011 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.

   They shall apply those provisions from 1 February 2012.

   When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

Article 3

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

The following entry for the substance warfarin is added in Annex I to Directive 98/8/EC:

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions (*)
"(**) [OPOCE: please insert substance number]	Warfarin	(RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin EC No: 201-377-6 CAS No: 81-81-2	990 g/kg	1 February 2012	31 January 2014	31 January 2017	14	The active substance shall be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed. Member States shall ensure that authorisations are subject to the following conditions: (1) The nominal concentration of the active substance shall not exceed 790 mg/kg and only ready-for-use baits shall be authorised. (2) Products shall contain an aversive agent and, where appropriate, a dye. (3) Primary and secondary exposure of humans, non-target animals and the environment are minimised, by considering and applying all appropriate and available risk mitigation measures. These include, amongst others, the possibility of restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait

No	Common Name	IUPAC Name Identification Numbers	Minimum purity of the active substance in the biocidal product as placed on the market	Date of inclusion	Deadline for compliance with Article 16(3) (except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)	Expiry date of inclusion	Product type	Specific provisions (*)
								boxes."

(*) For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm

COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels,
C(2009)XXX final

Draft

COMMISSION DECISION

of […]

concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market

Draft

COMMISSION DECISION

of

concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market[1], and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market[2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC.

(2) For a number of substance/product type combinations included in that list, either all participants have discontinued their participation from the review programme, or no complete dossier was received within the time period specified in Articles 9 and 12(3) of Regulation (EC) No 1451/2007 by the Member State designated as Rapporteur for the evaluation.

(3) Consequently, and pursuant to Articles 11(2), 12(1) and 13(5) of Regulation (EC) No 1451/2007, the Commission informed the Member States accordingly. That information was also made public by electronic means on 13 January 2009, 11 February 2009 and 11 March 2009.

(4) Within the period of three months from those publications, no person or Member State indicated an interest in taking over the role of participant for the substances and product-types concerned.

(5) Pursuant to Article 12(5) of Regulation (EC) No 1451/2007, the substances and product types concerned should therefore not be included in Annexes I, IA or IB to Directive 98/8/EC.

---

1 OJ L 123, 24.4.1998, p. 1.

2 OJ L 325, 11.12.2007, p. 3.

(6) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Biocidal Products,

HAS ADOPTED THIS DECISION:

Article 1

The substances and product-types indicated in the Annex to this Decision shall not be included in Annexes I, IA or IB to Directive 98/8/EC.

Article 2

This Decision is addressed to the Member States.

Done at Brussels, […]

For the Commission
Stavros DIMAS
Member of the Commission

ANNEX

Substances and product types not to be included in Annexes I, IA or IB to Directive 98/8/EC

Name	EC number	CAS number	Product-type	RMS
Bis[1-cyclohexyl-1,2-di(hydroxy-.kappa.O)diazeniumato(2-)]-copper		312600-89-8	11	AT
Cyclohexylhydroxydiazene 1-oxide, potassium salt		66603-10-9	11	AT
Peroxyoctanoic acid		33734-57-5	11	FR
Peroxyoctanoic acid		33734-57-5	12	FR
Bis[1-cyclohexyl-1,2-di(hydroxy-.kappa.O)diazeniumato(2-)]-copper		312600-89-8	12	AT
Bronopol	200-143-0	52-51-7	7	ES
Bronopol	200-143-0	52-51-7	10	ES
Chlorocresol	200-431-6	59-50-7	10	FR
Formic acid	200-579-1	64-18-6	9	BE
Benzoic acid	200-618-2	65-85-0	11	DE
Propan-2-ol	200-661-7	67-63-0	9	DE
Propan-2-ol	200-661-7	67-63-0	10	DE
Propan-2-ol	200-661-7	67-63-0	11	DE
Propan-2-ol	200-661-7	67-63-0	12	DE
Ethylene oxide	200-849-9	75-21-8	20	N
2-chloroacetamide	201-174-2	79-07-2	7	EE
2-chloroacetamide	201-174-2	79-07-2	9	EE
2-chloroacetamide	201-174-2	79-07-2	10	EE
2-chloroacetamide	201-174-2	79-07-2	11	EE
Glycollic acid	201-180-5	79-14-1	12	LT
L-(+)-lactic acid	201-196-2	79-33-4	20	DE
Symclosene	201-782-8	87-90-1	7	UK
Symclosene	201-782-8	87-90-1	9	UK
Dichlorophen	202-567-1	97-23-4	7	IE
Dichlorophen	202-567-1	97-23-4	9	IE
Dichlorophen	202-567-1	97-23-4	10	IE
Dichlorophen	202-567-1	97-23-4	11	IE
Dichlorophen	202-567-1	97-23-4	12	IE
Hexa-2,4-dienoic acid / Sorbic acid	203-768-7	110-44-1	7	DE
Hexa-2,4-dienoic acid / Sorbic acid	203-768-7	110-44-1	9	DE
Hexa-2,4-dienoic acid / Sorbic acid	203-768-7	110-44-1	10	DE
Glutaral	203-856-5	111-30-8	7	FI
Glutaral	203-856-5	111-30-8	9	FI
Glutaral	203-856-5	111-30-8	10	FI
Glutaral	203-856-5	111-30-8	22	FI
2-Phenoxyethanol	204-589-7	122-99-6	7	UK
2-Phenoxyethanol	204-589-7	122-99-6	10	UK
2-Phenoxyethanol	204-589-7	122-99-6	11	UK
Cetylpyridinium chloride	204-593-9	123-03-5	6	UK
Cetylpyridinium chloride	204-593-9	123-03-5	7	UK
Cetylpyridinium chloride	204-593-9	123-03-5	9	UK
Cetylpyridinium chloride	204-593-9	123-03-5	20	UK
Carbon dioxide	204-696-9	124-38-9	15	FR
Carbon dioxide	204-696-9	124-38-9	20	FR
Nitromethylidynetrimethanol	204-769-5	126-11-4	11	UK
Nitromethylidynetrimethanol	204-769-5	126-11-4	12	UK
Tosylchloramide sodium	204-854-7	127-65-1	9	ES

Tosylchloramide sodium	204-854-7	127-65-1	10	ES
Potassium dimethyldithiocarbamate	204-875-1	128-03-0	10	UK
Sodium dimethyldithiocarbamate	204-876-7	128-04-1	10	UK
Captan	205-087-0	133-06-2	7	IT
Captan	205-087-0	133-06-2	9	IT
Captan	205-087-0	133-06-2	10	IT
N-(trichloromethylthio)phthalimide / Folpet	205-088-6	133-07-3	10	IT
N,N-diethyl-m-toluamide	205-149-7	134-62-3	22	SE
Thiram	205-286-2	137-26-8	7	BE
Thiram	205-286-2	137-26-8	10	BE
Thiram	205-286-2	137-26-8	11	BE
Thiram	205-286-2	137-26-8	12	BE
Ziram	205-288-3	137-30-4	7	BE
Ziram	205-288-3	137-30-4	9	BE
Ziram	205-288-3	137-30-4	10	BE
Ziram	205-288-3	137-30-4	11	BE
Ziram	205-288-3	137-30-4	12	BE
Potassium methyldithiocarbamate	205-292-5	137-41-7	9	CZ
Potassium methyldithiocarbamate	205-292-5	137-41-7	11	CZ
Potassium methyldithiocarbamate	205-292-5	137-41-7	12	CZ
Metam-sodium	205-293-0	137-42-8	12	BE
Metam-sodium	205-293-0	137-42-8	20	BE
Disodium cyanodithiocarbamate	205-346-8	138-93-2	9	CZ
Disodium cyanodithiocarbamate	205-346-8	138-93-2	11	CZ
Disodium cyanodithiocarbamate	205-346-8	138-93-2	12	CZ
1,3-bis(hydroxymethyl)urea	205-444-0	140-95-4	9	HU
1,3-bis(hydroxymethyl)urea	205-444-0	140-95-4	11	HU
1,3-bis(hydroxymethyl)urea	205-444-0	140-95-4	12	HU
Nabam	205-547-0	142-59-6	9	PL
Nabam	205-547-0	142-59-6	10	PL
Nabam	205-547-0	142-59-6	11	PL
Nabam	205-547-0	142-59-6	12	PL
Thiabendazole	205-725-8	148-79-8	11	ES
Thiabendazole	205-725-8	148-79-8	12	ES
Thiabendazole	205-725-8	148-79-8	20	ES
Dazomet	208-576-7	533-74-4	7	BE
Dazomet	208-576-7	533-74-4	9	BE
Dazomet	208-576-7	533-74-4	10	BE
Dazomet	208-576-7	533-74-4	11	BE
Dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide / Tolylfluanid	211-986-9	731-27-1	10	FI
Hydroxyl-2-pyridone	212-506-0	822-89-9	9	FR
Hydroxyl-2-pyridone	212-506-0	822-89-9	10	FR
Hydroxyl-2-pyridone	212-506-0	822-89-9	11	FR
Hydroxyl-2-pyridone	212-506-0	822-89-9	12	FR
2,6-dimethyl-1,3-dioxan-4-yl acetate	212-579-9	828-00-2	11	AT
2,6-dimethyl-1,3-dioxan-4-yl acetate	212-579-9	828-00-2	12	AT
Dichlofluanid	214-118-7	1085-98-9	10	UK
4,5-dichloro-3H-1,2-dithiol-3-one	214-754-5	1192-52-5	9	PL
4,5-dichloro-3H-1,2-dithiol-3-one	214-754-5	1192-52-5	11	PL
4,5-dichloro-3H-1,2-dithiol-3-one	214-754-5	1192-52-5	12	PL
Zinc sulphide	215-251-3	1314-98-3	7	UK
Zinc sulphide	215-251-3	1314-98-3	9	UK
Zinc sulphide	215-251-3	1314-98-3	10	UK
Disodium tetraborate, anhydrous	215-540-4	1330-43-4	7	NL
Disodium tetraborate, anhydrous	215-540-4	1330-43-4	9	NL
Disodium tetraborate, anhydrous	215-540-4	1330-43-4	10	NL
2,4-dichlorobenzyl alcohol	217-210-5	1777-82-8	7	CZ

2,4-dichlorobenzyl alcohol	217-210-5	1777-82-8	9	CZ
2,4-dichlorobenzyl alcohol	217-210-5	1777-82-8	10	CZ
2,4-dichlorobenzyl alcohol	217-210-5	1777-82-8	12	CZ
Chlorothalonil	217-588-1	1897-45-6	7	NL
Chlorothalonil	217-588-1	1897-45-6	9	NL
Chlorothalonil	217-588-1	1897-45-6	10	NL
Fluometuron	218-500-4	2164-17-2	7	EL
Fluometuron	218-500-4	2164-17-2	9	EL
Fluometuron	218-500-4	2164-17-2	10	EL
Fluometuron	218-500-4	2164-17-2	11	EL
Fluometuron	218-500-4	2164-17-2	12	EL
N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine	219-145-8	2372-82-9	9	PT
N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine	219-145-8	2372-82-9	10	PT
2,2'-dithiobis[N-methylbenzamide]	219-768-5	2527-58-4	7	PL
2,2'-dithiobis[N-methylbenzamide]	219-768-5	2527-58-4	9	PL
2,2'-dithiobis[N-methylbenzamide]	219-768-5	2527-58-4	12	PL
1,2-benzisothiazol-3(2H)-one	220-120-9	2634-33-5	7	ES
1,2-benzisothiazol-3(2H)-one	220-120-9	2634-33-5	10	ES
1,2-benzisothiazol-3(2H)-one	220-120-9	2634-33-5	22	ES
2-methyl-2H-isothiazol-3-one	220-239-6	2682-20-4	7	SI
2-methyl-2H-isothiazol-3-one	220-239-6	2682-20-4	9	SI
2-methyl-2H-isothiazol-3-one	220-239-6	2682-20-4	10	SI
2-methyl-2H-isothiazol-3-one	220-239-6	2682-20-4	22	SI
Sodium dichloroisocyanurate dihydrate	220-767-7	51580-86-0	9	UK
Troclosene sodium	220-767-7	2893-78-9	9	UK
Bis(trichloromethyl) sulphone	221-310-4	3064-70-8	9	LT
Bis(trichloromethyl) sulphone	221-310-4	3064-70-8	10	LT
Bis(trichloromethyl) sulphone	221-310-4	3064-70-8	11	LT
Bis(trichloromethyl) sulphone	221-310-4	3064-70-8	12	LT
Bis(trichloromethyl) sulphone	221-310-4	3064-70-8	22	LT
(ethylenedioxy)dimethanol	222-720-6	3586-55-8	9	PL
Dipyrithione	223-024-5	3696-28-4	9	SE
Sodium 2,4,6-trichlorophenolate	223-246-2	3784-03-0	9	IE
Pyridine-2-thiol 1-oxide, sodium salt	223-296-5	3811-73-2	11	SE
Pyridine-2-thiol 1-oxide, sodium salt	223-296-5	3811-73-2	12	SE
Methenamine 3-chloroallylochloride	223-805-0	4080-31-3	9	PL
2,2',2"-(hexahydro-1,3,5-triazine-1,3,5-triyl)triethanol	225-208-0	4719-04-4	9	PL
Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione	226-408-0	5395-50-6	9	ES
Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione	226-408-0	5395-50-6	10	ES
N,N'-methylenebismorpholine	227-062-3	5625-90-1	9	AT
N,N'-methylenebismorpholine	227-062-3	5625-90-1	11	AT
Terbuthylazine	227-637-9	5915-41-3	11	UK
Terbuthylazine	227-637-9	5915-41-3	12	UK
(R)-p-mentha-1,8-diene	227-813-5	5989-27-5	12	PT
Methylene dithiocyanate	228-652-3	6317-18-6	7	FR
Methylene dithiocyanate	228-652-3	6317-18-6	9	FR
Methylene dithiocyanate	228-652-3	6317-18-6	10	FR
Methylene dithiocyanate	228-652-3	6317-18-6	11	FR
Methylene dithiocyanate	228-652-3	6317-18-6	22	FR
1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione	229-222-8	6440-58-0	11	PL
1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione	229-222-8	6440-58-0	12	PL
(2-bromo-2-nitrovinyl)benzene	230-515-8	7166-19-0	11	SK
(2-bromo-2-nitrovinyl)benzene	230-515-8	7166-19-0	12	SK
Didecyldimethylammonium chloride	230-525-2	7173-51-5	7	IT
Didecyldimethylammonium chloride	230-525-2	7173-51-5	9	IT
Prometryn	230-711-3	7287-19-6	7	PT

Prometryn	230-711-3	7287-19-6	9	PT
Prometryn	230-711-3	7287-19-6	10	PT
Prometryn	230-711-3	7287-19-6	11	PT
Prometryn	230-711-3	7287-19-6	12	PT
Sulphur dioxide	231-195-2	7446-09-5	9	DE
Sulphur dioxide	231-195-2	7446-09-5	11	DE
Sulphur dioxide	231-195-2	7446-09-5	12	DE
Sulphur dioxide	231-195-2	7446-09-5	20	DE
Sulphur dioxide	231-195-2	7446-09-5	22	DE
Calcium dihexa-2,4-dienoate	231-321-6	7492-55-9	7	DE
Calcium dihexa-2,4-dienoate	231-321-6	7492-55-9	9	DE
Calcium dihexa-2,4-dienoate	231-321-6	7492-55-9	20	DE
Iodine	231-442-4	7553-56-2	7	SE
Iodine	231-442-4	7553-56-2	9	SE
Iodine	231-442-4	7553-56-2	10	SE
Iodine	231-442-4	7553-56-2	11	SE
Silicon dioxide – amorphous	231-545-4	7631-86-9	20	FR
Sodium hydrogensulphite	231-548-0	7631-90-5	9	DE
Sodium hydrogensulphite	231-548-0	7631-90-5	11	DE
Sodium hydrogensulphite	231-548-0	7631-90-5	12	DE
Sodium hydrogensulphite	231-548-0	7631-90-5	20	DE
Sodium hydrogensulphite	231-548-0	7631-90-5	22	DE
Sodium bromide	231-599-9	7647-15-6	7	NL
Sodium bromide	231-599-9	7647-15-6	9	NL
Disodium disulphite	231-673-0	7681-57-4	9	DE
Disodium disulphite	231-673-0	7681-57-4	11	DE
Disodium disulphite	231-673-0	7681-57-4	12	DE
Disodium disulphite	231-673-0	7681-57-4	20	DE
Disodium disulphite	231-673-0	7681-57-4	22	DE
7a-ethyldihydro-1H,3H,5H-oxazolo[3,4-c]oxazole	231-810-4	7747-35-5	11	PL
7a-ethyldihydro-1H,3H,5H-oxazolo[3,4-c]oxazole	231-810-4	7747-35-5	12	PL
Sodium sulphite	231-821-4	7757-83-7	9	DE
Sodium sulphite	231-821-4	7757-83-7	11	DE
Sodium sulphite	231-821-4	7757-83-7	12	DE
Sodium sulphite	231-821-4	7757-83-7	20	DE
Sodium sulphite	231-821-4	7757-83-7	22	DE
Sodium chlorite	231-836-6	7758-19-2	11	PT
Sodium chlorite	231-836-6	7758-19-2	12	PT
Sodium chlorite	231-836-6	7758-19-2	20	PT
Sodium chlorate	231-887-4	7775-09-9	11	PT
Sodium chlorate	231-887-4	7775-09-9	12	PT
Lignin	232-682-2	9005-53-2	7	EL
Lignin	232-682-2	9005-53-2	9	EL
Lignin	232-682-2	9005-53-2	10	EL
Lignin	232-682-2	9005-53-2	11	EL
Lignin	232-682-2	9005-53-2	12	EL
Boric acid	233-139-2	10043-35-3	7	NL
Boric acid	233-139-2	10043-35-3	9	NL
Boric acid	233-139-2	10043-35-3	10	NL
Boric acid	233-139-2	10043-35-3	11	NL
Boric acid	233-139-2	10043-35-3	12	NL
Chlorine dioxide	233-162-8	10049-04-4	20	PT
Potassium sulphite	233-321-1	10117-38-1	9	DE
Potassium sulphite	233-321-1	10117-38-1	11	DE
Potassium sulphite	233-321-1	10117-38-1	12	DE
Potassium sulphite	233-321-1	10117-38-1	20	DE
Potassium sulphite	233-321-1	10117-38-1	22	DE
Sodium hydrogen 2,2’methylenebis[4-chlorophenolate]	233-457-1	10187-52-7	7	LV

Sodium hydrogen 2,2’methylenebis[4-chlorophenolate]	233-457-1	10187-52-7	9	LV
Sodium hydrogen 2,2’methylenebis[4-chlorophenolate]	233-457-1	10187-52-7	10	LV
Sodium hydrogen 2,2’methylenebis[4-chlorophenolate]	233-457-1	10187-52-7	11	LV
Sodium hydrogen 2,2’methylenebis[4-chlorophenolate]	233-457-1	10187-52-7	12	LV
2,2-dibromo-2-cyanoacetamide	233-539-7	10222-01-2	3	DK
2,2-dibromo-2-cyanoacetamide	233-539-7	10222-01-2	7	DK
2,2-dibromo-2-cyanoacetamide	233-539-7	10222-01-2	9	DK
2,2-dibromo-2-cyanoacetamide	233-539-7	10222-01-2	10	DK
Carbendazim	234-232-0	10605-21-7	11	DE
Carbendazim	234-232-0	10605-21-7	12	DE
Disodium octaborate tetrahydrate	234-541-0	12280-03-4	7	NL
Disodium octaborate tetrahydrate	234-541-0	12280-03-4	9	NL
Disodium octaborate tetrahydrate	234-541-0	12280-03-4	10	NL
Disodium octaborate tetrahydrate	234-541-0	12280-03-4	11	NL
Disodium octaborate tetrahydrate	234-541-0	12280-03-4	12	NL
Trimagnesium diphosphide	235-023-7	12057-74-8	23	DE
Ammonium bromide	235-183-8	12124-97-9	7	SE
Ammonium bromide	235-183-8	12124-97-9	9	SE
Hexaboron dizinc undecaoxide / Zinc borate	235-804-2	12767-90-7	9	ES
Dodecylguanidine monohydrochloride	237-030-0	13590-97-1	7	ES
Dodecylguanidine monohydrochloride	237-030-0	13590-97-1	9	ES
Dodecylguanidine monohydrochloride	237-030-0	13590-97-1	10	ES
Dodecylguanidine monohydrochloride	237-030-0	13590-97-1	12	ES
Dodecylguanidine monohydrochloride	237-030-0	13590-97-1	22	ES
Bromine chloride	237-601-4	13863-41-7	12	NL
(benzyloxy)methanol	238-588-8	14548-60-8	9	UK
(benzyloxy)methanol	238-588-8	14548-60-8	10	UK
(benzyloxy)methanol	238-588-8	14548-60-8	11	UK
Bis(1-hydroxy-1H-pyridine-2-thionato-O,S)copper	238-984-0	14915-37-8	9	SE
Chlorotoluron	239-592-2	15545-48-9	7	ES
Chlorotoluron	239-592-2	15545-48-9	9	ES
Chlorotoluron	239-592-2	15545-48-9	10	ES
Chlorotoluron	239-592-2	15545-48-9	11	ES
Chlorotoluron	239-592-2	15545-48-9	12	ES
Sodium p-chloro-m-cresolate	239-825-8	15733-22-9	10	FR
Dipotassium disulphite	240-795-3	16731-55-8	9	DE
Dipotassium disulphite	240-795-3	16731-55-8	11	DE
Dipotassium disulphite	240-795-3	16731-55-8	12	DE
Dipotassium disulphite	240-795-3	16731-55-8	20	DE
Dipotassium disulphite	240-795-3	16731-55-8	22	DE
Benzoxonium chloride	243-008-1	19379-90-9	9	CY
p-[(diiodomethyl)sulphonyl]toluene	243-468-3	20018-09-1	12	UK
(benzothiazol-2-ylthio)methyl thiocyanate	244-445-0	21564-17-0	7	N
(benzothiazol-2-ylthio)methyl thiocyanate	244-445-0	21564-17-0	10	N
(benzothiazol-2-ylthio)methyl thiocyanate	244-445-0	21564-17-0	11	N
Potassium (E,E)-hexa-2,4-dienoate	246-376-1	24634-61-5	7	DE
Potassium (E,E)-hexa-2,4-dienoate	246-376-1	24634-61-5	9	DE
Potassium (E,E)-hexa-2,4-dienoate	246-376-1	24634-61-5	10	DE
.alpha.,.alpha.',.alpha."-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol	246-764-0	25254-50-6	9	AT
2-octyl-2H-isothiazol-3-one	247-761-7	26530-20-1	12	UK
Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride	248-595-8	27668-52-6	10	ES
N'-tert-butyl-N-cyclopropyl-6-(methylthio)-1,3,5-triazine-2,4-diamine	248-872-3	28159-98-0	9	NL
Bromochloro-5,5-dimethylimidazolidine-2,4-dione	251-171-5	32718-18-6	9	NL
3-(4-isopropylphenyl)-1,1-dimethylurea / Isoproturon	251-835-4	34123-59-6	9	DE
3-(4-isopropylphenyl)-1,1-dimethylurea / Isoproturon	251-835-4	34123-59-6	11	DE

3-(4-isopropylphenyl)-1,1-dimethylurea / Isoproturon	251-835-4	34123-59-6	12	DE
1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole / Imazalil	252-615-0	35554-44-0	20	DE
2-bromo-2-(bromomethyl)pentanedinitrile	252-681-0	35691-65-7	7	CZ
2-bromo-2-(bromomethyl)pentanedinitrile	252-681-0	35691-65-7	9	CZ
2-bromo-2-(bromomethyl)pentanedinitrile	252-681-0	35691-65-7	10	CZ
2-bromo-2-(bromomethyl)pentanedinitrile	252-681-0	35691-65-7	11	CZ
4,4-dimethyloxazolidine	257-048-2	51200-87-4	11	UK
.alpha.-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate / Cypermethrin	257-842-9	52315-07-8	9	BE
m-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate / Permethrin	258-067-9	52645-53-1	22	IE
3-iodo-2-propynyl butylcarbamate	259-627-5	55406-53-6	11	DK
Tetrakis(hydroxymethyl)phosphonium sulphate(2:1)	259-709-0	55566-30-8	9	MT
1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole / Propiconazole	262-104-4	60207-90-1	10	FI
1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole / Propiconazole	262-104-4	60207-90-1	12	FI
1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole / Propiconazole	262-104-4	60207-90-1	20	FI
4,5-dichloro-2-octyl-2H-isothiazol-3-one	264-843-8	64359-81-5	12	N
3,3'-methylenebis[5-methyloxazolidine] / Oxazolidin	266-235-8	66204-44-2	10	AT
Cis-4-[3-(p-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine / Fenpropimorph	266-719-9	67564-91-4	7	ES
Cis-4-[3-(p-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine / Fenpropimorph	266-719-9	67564-91-4	9	ES
Cis-4-[3-(p-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine / Fenpropimorph	266-719-9	67564-91-4	10	ES
Cis-4-[3-(p-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine / Fenpropimorph	266-719-9	67564-91-4	12	ES
Quaternary ammonium compounds, benzyl-C12-18-alkyldimethyl, chlorides	269-919-4	68391-01-5	7	IT
Quaternary ammonium compounds, benzyl-C12-18-alkyldimethyl, chlorides	269-919-4	68391-01-5	9	IT
Quaternary ammonium compounds, benzyl-C12-18-alkyldimethyl, chlorides	269-919-4	68391-01-5	17	IT
Quaternary ammonium compounds, benzyl-C12-16-alkyldimethyl, chlorides	270-325-2	68424-85-1	7	IT
Quaternary ammonium compounds, benzyl-C12-16-alkyldimethyl, chlorides	270-325-2	68424-85-1	9	IT
Quaternary ammonium compounds, di-C8-10-alkyldimethyl, chlorides	270-331-5	68424-95-3	7	IT
Quaternary ammonium compounds, di-C8-10-alkyldimethyl, chlorides	270-331-5	68424-95-3	9	IT
Quaternary ammonium compounds, di-C8-10-alkyldimethyl, chlorides	270-331-5	68424-95-3	22	IT
Quaternary ammonium compounds, benzyl-C12-18-alkyldimethyl, salts with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1)	273-545-7	68989-01-5	11	MT
Quaternary ammonium compounds, benzyl-C12-18-alkyldimethyl, salts with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1)	273-545-7	68989-01-5	12	MT
Sodium N-(hydroxymethyl)glycinate	274-357-8	70161-44-3	7	AT
Pentapotassium bis(peroxymonosulphate) bis(sulphate)	274-778-7	70693-62-8	11	SI
Pentapotassium bis(peroxymonosulphate) bis(sulphate)	274-778-7	70693-62-8	12	SI
1,3-didecyl-2-methyl-1H-imidazolium chloride	274-948-0	70862-65-6	7	CZ
1,3-didecyl-2-methyl-1H-imidazolium chloride	274-948-0	70862-65-6	10	CZ
1,3-didecyl-2-methyl-1H-imidazolium chloride	274-948-0	70862-65-6	11	CZ
1,3-didecyl-2-methyl-1H-imidazolium chloride	274-948-0	70862-65-6	12	CZ

Tributyltetradecylphosphonium chloride	279-808-2	81741-28-8	9	PL
Tributyltetradecylphosphonium chloride	279-808-2	81741-28-8	11	PL
Tributyltetradecylphosphonium chloride	279-808-2	81741-28-8	12	PL
Quaternary ammonium compounds, benzyl-C12-14-alkyldimethyl, chlorides	287-089-1	85409-22-9	7	IT
Quaternary ammonium compounds, benzyl-C12-14-alkyldimethyl, chlorides	287-089-1	85409-22-9	9	IT
Quaternary ammonium compounds, benzyl-C12-14-alkyldimethyl, chlorides	287-089-1	85409-22-9	17	IT
Quaternary ammonium compounds, C12-14-alkyl[(ethylphenyl)methyl]dimethyl, chlorides	287-090-7	85409-23-0	9	IT
Quaternary ammonium compounds, C12-14-alkyl[(ethylphenyl)methyl]dimethyl, chlorides	287-090-7	85409-23-0	17	IT
Urea, N,N'-bis(hydroxymethyl)-, reaction products with 2-(2-butoxyethoxy)ethanol, ethylene glycol and formaldehyde	292-348-7	90604-54-9	11	PL
Urea, N,N'-bis(hydroxymethyl)-, reaction products with 2-(2-butoxyethoxy)ethanol, ethylene glycol and formaldehyde	292-348-7	90604-54-9	12	PL
Quaternary ammonium compounds, [2-[[2-[(2-carboxyethyl)(2-hydroxyethyl)amino]ethyl]amino]-2-oxoethyl]coco alkyldimethyl, hydroxides, inner salts	309-206-8	100085-64-1	7	LT
Quaternary ammonium compounds, [2-[[2-[(2-carboxyethyl)(2-hydroxyethyl)amino]ethyl]amino]-2-oxoethyl]coco alkyldimethyl, hydroxides, inner salts	309-206-8	100085-64-1	10	LT
Quaternary ammonium compounds, [2-[[2-[(2-carboxyethyl)(2-hydroxyethyl)amino]ethyl]amino]-2-oxoethyl]coco alkyldimethyl, hydroxides, inner salts	309-206-8	100085-64-1	11	LT
Quaternary ammonium compounds, [2-[[2-[(2-carboxyethyl)(2-hydroxyethyl)amino]ethyl]amino]-2-oxoethyl]coco alkyldimethyl, hydroxides, inner salts	309-206-8	100085-64-1	12	LT
Mixture of: (C8-18)alkylbis(2-hydroxyethyl)ammonium bis(2-ethylhexyl)phosphate;(C8-18)alkylbis(2-hydroxyethyl)ammonium 2-ethylhexylhydrogenphosphate	404-690-8	68132-19-4	7	PL
Mixture of: (C8-18)alkylbis(2-hydroxyethyl)ammonium bis(2-ethylhexyl)phosphate;(C8-18)alkylbis(2-hydroxyethyl)ammonium 2-ethylhexylhydrogenphosphate	404-690-8	68132-19-4	9	PL
6-(phthalimido)peroxyhexanoic acid	410-850-8	128275-31-0	11	IT
6-(phthalimido)peroxyhexanoic acid	410-850-8	128275-31-0	12	IT
Tetrachlorodecaoxide complex	420-970-2	92047-76-2	3	DE
cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride	426-020-3	51229-78-8	9	PL
cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride	426-020-3	51229-78-8	12	PL
Thiamethoxam	428-650-4	153719-23-4	9	ES
5-chloro-2-(4-chlorphenoxy)phenol	429-290-0	3380-30-1	9	AT
3-benzo(b)thien-2-yl-5,6-dihydro-1,4,2-oxathiazine,4-oxide	431-030-6	163269-30-5	7	PT
3-benzo(b)thien-2-yl-5,6-dihydro-1,4,2-oxathiazine,4-oxide	431-030-6	163269-30-5	10	PT
Reaction product of dimethyl adipate, dimethyl glutarate, dimethyl succinate with hydrogen peroxide / Perestane	432-790-1	-	11	HU
Reaction product of dimethyl adipate, dimethyl glutarate, dimethyl succinate with hydrogen peroxide / Perestane	432-790-1	-	12	HU
Bis(3-aminopropyl)octylamine	433-340-7	86423-37-2	11	CZ
Bis(3-aminopropyl)octylamine	433-340-7	86423-37-2	12	CZ
Amines, n-C10-16-alkyltrimethylenedi-, reaction products with chloroacetic acid	Mixture	139734-65-9	7	IE
Amines, n-C10-16-alkyltrimethylenedi-, reaction products with chloroacetic acid	Mixture	139734-65-9	10	IE
Amines, n-C10-16-alkyltrimethylenedi-, reaction products with chloroacetic acid	Mixture	139734-65-9	11	IE
Amines, n-C10-16-alkyltrimethylenedi-, reaction products with chloroacetic acid	Mixture	139734-65-9	12	IE
Mixture of 1-phenoxypropan-2-ol (EINECS 212-222-7) and 2-	Mixture	-	10	UK

phenoxypropanol (EINECS 224-027-4)				
Mixture of 1-phenoxypropan-2-ol (EINECS 212-222-7) and 2-phenoxypropanol (EINECS 224-027-4)	Mixture	-	11	UK
Mixture of 5-chloro-2-methyl-2H-isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)	Mixture	55965-84-9	7	FR
Mixture of 5-chloro-2-methyl-2H-isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)	Mixture	55965-84-9	9	FR
Mixture of 5-chloro-2-methyl-2H-isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)	Mixture	55965-84-9	10	FR
Quaternary ammonium iodides	Mixture	308074-50-2	7	ES
Quaternary ammonium compounds (benzylalkyldimethyl (alkyl from C8-C22, saturated and unsaturated, tallow alkyl, coco alkyl, and soya alkyl) chlorides, bromides, or hydroxides) / BKC	Mixture of EINECS listed substances	-	7	IT
Quaternary ammonium compounds (dialkyldimethyl (alkyl from C6-C18, saturated and unsaturated, and tallow alkyl, coco alkyl, and soya alkyl) chlorides, bromides, or methylsulphates) / DDAC	Mixture of EINECS listed substances	-	7	IT
Quaternary ammonium compounds (dialkyldimethyl (alkyl from C6-C18, saturated and unsaturated, and tallow alkyl, coco alkyl, and soya alkyl) chlorides, bromides, or methylsulphates) / DDAC	Mixture of EINECS listed substances	-	9	IT
Quaternary ammonium compounds (benzylalkyldimethyl (alkyl from C8-C22, saturated and unsaturated, tallow alkyl, coco alkyl, and soya alkyl) chlorides, bromides, or hydroxides) / BKC	Mixture of EINECS listed substances	-	9	IT
Sodium lignosulfonate	Natural Polymer	8061-51-6	12	HU
Silver sodium hydrogen zirconium phosphate	Not yet allocated	422-570-3	10	SE
[1.alpha.(S*),3.alpha.]-(.alpha.)-cyano-(3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2.2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate / alpha-Cypermethrin	Plant protection product	67375-30-8	9	BE
4-Bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile / Chlorfenapyr	Plant protection product	122453-73-0	7	PT
4-Bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile / Chlorfenapyr	Plant protection product	122453-73-0	9	PT
4-Bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile / Chlorfenapyr	Plant protection product	122453-73-0	10	PT
4-Bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile / Chlorfenapyr	Plant protection product	122453-73-0	12	PT
Aluminium sodium silicate-silver complex / Silver zeolite	Plant protection product	130328-18-6	7	SE
Monohydro chloride of polymer of N,N'''-1,6-hexanediylbis[N'-cyanoguanidine] (EINECS 240-032-4) and hexamethylenediamine (EINECS 204-679-6) / Polyhexamethylene biguanide (monomer: 1,5-bis(trimethylen)-guanylguanidinium monohydrochloride)	Polymer	27083-27-8 / 32289-58-0	12	FR
Monohydro chloride of polymer of N,N'''-1,6-hexanediylbis[N'-cyanoguanidine] (EINECS 240-032-4) and	Polymer	27083-27-8 / 32289-58-0	22	FR

hexamethylenediamine (EINECS 204-679-6) / Polyhexamethylene biguanide (monomer: 1,5-bis(trimethylen)-guanylguanidinium monohydrochloride)				
N,N,N',N'–Tetramethylethylenediaminebis(2-chloroethyl)ether copolymer	Polymer	31075-24-8	9	UK
N,N,N',N'–Tetramethylethylenediaminebis(2-chloroethyl)ether copolymer	Polymer	31075-24-8	11	UK
N,N,N',N'–Tetramethylethylenediaminebis(2-chloroethyl)ether copolymer	Polymer	31075-24-8	12	UK
N-Didecyl-N-dipolyethoxyammonium borate / Didecylpolyoxethylammonium borate	Polymer	214710-34-6	9	EL
N-Didecyl-N-dipolyethoxyammonium borate / Didecylpolyoxethylammonium borate	Polymer	214710-34-6	10	EL
N-Didecyl-N-dipolyethoxyammonium borate / Didecylpolyoxethylammonium borate	Polymer	214710-34-6	11	EL
N-Didecyl-N-dipolyethoxyammonium borate / Didecylpolyoxethylammonium borate	Polymer	214710-34-6	12	EL
Poly(hexamethylenebiguanide)	Polymer	91403-50-8	10	FR
Poly(oxy-1,2-ethanediyl), .alpha.-[2-(didecylmethylammonio)ethyl]- .omega.-hydroxy-, propanoate (salt)	Polymer	94667-33-1	9	IT
Poly(oxy-1,2-ethanediyl), .alpha.-[2-(didecylmethylammonio)ethyl]- .omega.-hydroxy-, propanoate (salt)	Polymer	94667-33-1	11	IT
Poly(oxy-1,2-ethanediyl), .alpha.-[2-(didecylmethylammonio)ethyl]- .omega.-hydroxy-, propanoate (salt)	Polymer	94667-33-1	12	IT
Polymer of N-Methylmethanamine (EINECS 204-697-4 with (chloromethyl)oxirane (EINECS 203-439-8) / Polymeric quaternary ammonium chloride	Polymer	25988-97-0	12	HU
Polyvinylpyrrolidone iodine	Polymer	25655-41-8	7	SE
Polyvinylpyrrolidone iodine	Polymer	25655-41-8	9	SE
Polyvinylpyrrolidone iodine	Polymer	25655-41-8	10	SE
Polyvinylpyrrolidone iodine	Polymer	25655-41-8	11	SE